“These kinds of approvals are purely data-driven, and in both these vaccines Phase 2 immunogenicity has been well established. The question of approving a vaccine without adequate data does not arise as the expert panel minutely scans the national as well international data presented to them before granting an approval,” said DG-ICMR.
Posted from: this blog via Microsoft Flow.
No comments:
Post a Comment